OBJECTIVES: Oxaliplatin solution form is a new and safer formulation of oxaliplatin avoiding the reconstitution step during cytotoxic preparation. The main objective was to assess the economic impact using oxaliplatin concentrated solution compared with the lyophilised powder form from the hospital pharmacy point of view. METHODS: Due to the equivalent efficacy between the 2 formulations, a cost-minimisation analysis with a hospital perspective was performed comparing the solution versus the powder. A single-centre observational study was conducted in a French Cancer Centre. The cytotoxic preparations were assessed using the powder in a first time and the solution form in a second time. The same staff member manipulated both preparations in order to avoid any bias. Two independent observers collected the results from the 30 manipulations. The first endpoint assessed was preparation time. Secondary endpoint was overall cost associated with this preparation, which included costs associated to preparation time, material and cytotoxic waste management. RESULTS: The reconstitution step was avoided using the solution form. The time saved with the solution form versus the lyophilised powder was 139 seconds per preparation. The overall avoided cost represented €1.04 per preparation using oxaliplatin solution form. This total cost could be broken up into three components: costs associated to the preparation time (71%), material costs (27%) and the waste management costs (2%). For 100 patients treated receiving 10 cycles of chemotherapy, this represents a total saving of €1,040. CONCLUSION: Using oxaliplatin concentrated solution form represented a time saving and an economic benefit for the hospital pharmacist. In addition, this new solution form increases the safety aspects by reducing risk of preparation errors and risk of cytotoxic drug exposure for manipulators. It would be interesting to confirm those results in a multi-centric analysis.